Based on the vital functions of IGF-1 in lung progression and reports stating that low IGF levels after birth are associated with the further development of BPD, our study aimed to (i) illustrate whether recombinant human IGF-1 (rhIGF-1)/binding peptide 3 (BP3) could prevent the development of PH in experimental BPD and (ii) uncover the latent mechanism of rhIGF-1/BP3 in vascular growth, lung structure, and lung function to identify promising therapies for BPD treatment. This evidence concerns the gene IGF1 and bronchopulmonary dysplasia.